Liaison(s): Purvi Lad, Jordan Brustein
Amgen is a biotechnology company specializing in developing and manufacturing biologic and biosimilar medicines. They have been involved in the biosimilars market since 2011. In 2018, Amgen had global revenues of $23.75 billion. They have expertise in developing biologic medicines to treat oncology, inflammation, and cardiovascular diseases.
Amgen would like to successfully continue breaking into the biosimilars market, providing additional treatment options for biologic medicines. Amgen hopes to better understand the future market conditions for biosimilars. Through this Team Master’s Project (TMP), Amgen hopes to gain an external perspective on specific questions to help inform how to navigate the highly competitive biosimilar marketplace of the future.
To provide the external perspective, the KGI TMP team has assessed the strengths, weaknesses, opportunities, and challenges for three undisclosed biosimilars in Amgen’s pipeline. Feeding into this overarching deliverable, the team has completed in-depth secondary research to analyze the impact of new molecular entities and competing biosimilars for each of the three pipeline assets. Additionally, the team has completed a probability of technical and regulatory success (PTRS) commercial viability framework for each molecule which will be used annually for objective assessment of each pipeline asset’s PTRS within the fast evolving biosimilars marketplace. From the insights gained through secondary research and analysis of the molecules and corresponding markets, the KGI team also provided an external point of view on potential key swing factors affecting the U.S. biosimilars market as well as a few recommendations for novel lifecycle management strategies for assets in Amgen’s biosimilars pipeline asset.